Bevacizumab BS Nichi-Iko
Bevacizumab biosimilar developed by Nichi-Iko Pharmaceutical. Reference product Avastin.
About Bevacizumab BS Nichi-Iko
Bevacizumab BS Nichi-Iko is Nichi-Iko's own bevacizumab, the third bevacizumab biosimilar approved in Japan, in January 2022. Nichi-Iko is a large Japanese generics company and one of the few to develop its own biosimilars rather than market others' products.
Status by market
United States
Not listed by FDA.
European Union
Not listed by EMA.
United Kingdom
Not listed by MHRA.
Japan · Bevacizumab BS Nichi-Iko
Pharmaceuticals and Medical Devices Agency and MHLWApprovedCanada
Not listed by HC.
India
Not listed by CDSCO.
United Arab Emirates
Not listed by EDE.
Other developers in the same markets
Where Bevacizumab BS Nichi-Iko holds an approval, these are the other bevacizumab biosimilars approved in that market.
Same developer, other molecules
Other biosimilars in the Atlas developed by Nichi-Iko Pharmaceutical: Infliximab BS Nichiiko / AYUMI.
Chronology
- PMDAJan 2022Approved by MHLW
Sources
S020PMDA, list of approved biosimilar products in Japan (as of July 2026) Primary (regulator)
Planning bevacizumab biosimilar development?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultant